Literature DB >> 18674583

New vaccine approaches for seasonal and pandemic influenza.

Bram Palache1.   

Abstract

Inactivated influenza vaccines have been available since the late 1940s for the prevention of influenza disease. Based on the available scientific evidence, many public health authorities, including the World Health Organization, recommend annual use of these vaccines for specific populations, including the elderly. Despite these recommendations, actual vaccination uptake rates are very limited in many countries. Influenza vaccine research is confounded by the variable nature of the influenza viruses and annual influenza epidemics and by non-specific clinical diagnostic criteria. These confounding factors complicate evaluation not only of overall vaccine effectiveness, but also of the relative efficacy and effectiveness of different vaccine formulations. This paper summarizes recent advances in the development of seasonal and (pre-)pandemic vaccines, discusses the methodologic constraints on influenza vaccine research, and proposes measures to reduce the level of potential bias and confounding in influenza vaccine research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18674583     DOI: 10.1016/j.vaccine.2008.07.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

Authors:  R Colby Layton; Nikolai Petrovsky; Andrew P Gigliotti; Zemmie Pollock; Jennifer Knight; Nathaniel Donart; John Pyles; Kevin S Harrod; Peng Gao; Frederick Koster
Journal:  Vaccine       Date:  2011-07-06       Impact factor: 3.641

2.  Economic analysis of pandemic influenza vaccination strategies in Singapore.

Authors:  Vernon J Lee; Mei Yin Tok; Vincent T Chow; Kai Hong Phua; Eng Eong Ooi; Paul A Tambyah; Mark I Chen
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

3.  Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model.

Authors:  Germain J P Fernando; Xianfeng Chen; Tarl W Prow; Michael L Crichton; Emily J Fairmaid; Michael S Roberts; Ian H Frazer; Lorena E Brown; Mark A F Kendall
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

Review 4.  Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.

Authors:  Jördis J Ott; Janna Klein Breteler; John S Tam; Raymond C W Hutubessy; Mark Jit; Michiel R de Boer
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

5.  Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret.

Authors:  Robert Colby Layton; Andrew Gigliotti; Penny Armijo; Leslie Myers; Jennifer Knight; Nathaniel Donart; John Pyles; Sarah Vaughan; Jennifer Plourde; Ndingsa Fomukong; Kevin S Harrod; Peng Gao; Frederick Koster
Journal:  PLoS One       Date:  2011-06-07       Impact factor: 3.240

6.  RNA replicons - a new approach for influenza virus immunoprophylaxis.

Authors:  Gert Zimmer
Journal:  Viruses       Date:  2010-01-29       Impact factor: 5.818

7.  Construction of recombinant bacmid containing m2e-ctxb and producing the fusion protein in insect cell lines.

Authors:  Nima Mirzaei; Talat Mokhtari Azad; Rakhshandeh Nategh; Hoorieh Soleimanjahi; Nour Amirmozafari
Journal:  Iran Red Crescent Med J       Date:  2014-02-07       Impact factor: 0.611

Review 8.  Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.

Authors:  Hugo Arlegui; Kaatje Bollaerts; Francesco Salvo; Vincent Bauchau; Gaëlle Nachbaur; Bernard Bégaud; Nicolas Praet
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.